drugset / Trial / NCT00578929

Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients

NCT00578929

Phase 3 Completed 2388 enrolled Alcon Research
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to demonstrate the superiority of test article nasal spray relative to vehicle nasal spray for the treatment of seasonal allergic rhinitis for a 2 week period in patients aged 6 to 11 years with a history of seasonal allergic rhinitis.

Timeline

Start
2007-09
Primary completion
2008-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olopatadine Other / unclassified 0.6 % Intranasal